EFFICACY OF OSSEIN-HYDROXYAPATITE COMPLEX AS A PHARMACOLOGICAL CORRECTOR OF BONE LOSS (REVIEW)

The problem of osteoporosis is relevant due to the high frequency of its prevalence throughout the world. Complex mechanisms for maintaining bone mass biomass require various options for their pharmacological correction, so the range of proposed drugs is expanding. Among the debatable indications for the pharmacological correction of osteopenia and osteoporosis, the effectiveness and safety of the ossein-hydroxyapatite complex (OHC), which contributes to the preservation of mitogenic effects on bone cells, are specified. The literature review dis-cusses aspects of the use of OHC: in traumatology and surgery for problematic complicated fractures, the impact of both excess and deficiency of hormonal regulators in postmenopausal women or in conditions of long-term pharmacotherapy with glucocorticoids, age-related as-pects from childhood to old age correction by OHC of accompanying bone tissue imbalance in pediatrics and geriatrics are considered, as well as the mechanisms of the positive effect of OHC in experimental data are clarified. Among the unresolved debatable issues of clinical protocols, various dose aspects, duration of therapy and clarification of indications in accord-ance with the requirements of personalized medicine continue to remain.